Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Scynexis Inc
SCYXCurrent price
1.04 USD
0 USD (0.00%)
Last closed
1.04 USD
Company
www.scynexis.com
ISIN
US8112922005
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
40 978 656 USD
Yield for 12 month
-27.27 %
1Y
3Y
5Y
10Y
15Y
SCYX
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.67 USDP/E ratio
–Dividend Yield
–Current Year
+140 141 000 USD
Last Year
+5 091 000 USD
Current Quarter
+660 000 USD
Last Quarter
+736 000 USD
Current Year
+124 517 000 USD
Last Year
+4 463 000 USD
Current Quarter
+660 000 USD
Last Quarter
+736 000 USD
Key Figures SCYX
1 year
3 years
5 years
10 years
EBITDA
-52 365 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-26.72 %
PEG Ratio
–
Return On Equity TTM
-48.42 %
Wall Street Target Price
6.67 USD
Revenue TTM
8 566 000 USD
Book Value
1.54 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-62.50 %
Dividend Yield
–
Gross Profit TTM
12 851 000 USD
Earnings per share
-0.76 USD
Diluted Eps TTM
-0.76 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SCYX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SCYX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
17.07.2020
Stock Valuation SCYX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.41
Enterprise Value Revenue
0.44
Price Sales TTM
4.78
Enterprise Value EBITDA
0.055
Price Book MRQ
0.70
Financials SCYX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SCYX
For 52 weeks
1.06 USD
3.07 USD
50 Day MA
1.34 USD
Shares Short Prior Month
837 550
200 Day MA
1.68 USD
Short Ratio
5.04
Shares Short
795 428
Short Percent
2.77 %
BeatStart